NeoImmuneTech, Inc. (KOSDAQ:950220)

Total Valuation

NeoImmuneTech has a market cap or net worth of KRW 75.73 billion. The enterprise value is 66.33 billion.

Market Cap	75.73B
Enterprise Value	66.33B

Important Dates

The next estimated earnings date is Friday, November 14, 2025.

Earnings Date	Nov 14, 2025
Ex-Dividend Date	n/a

Share Statistics

NeoImmuneTech has 98.87 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	98.87M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.96%
Owned by Institutions (%)	n/a
Float	93.73M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	363.23
PB Ratio	3.19
P/TBV Ratio	4.20
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-1.91
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.81

Financial Position

The company has a current ratio of 1.64, with a Debt / Equity ratio of 0.47.

Current Ratio	1.64
Quick Ratio	0.91
Debt / Equity	0.47
Debt / EBITDA	n/a
Debt / FCF	-0.30
Interest Coverage	-14.02

Financial Efficiency

Return on equity (ROE) is -84.05% and return on invested capital (ROIC) is -45.62%.

Return on Equity (ROE)	-84.05%
Return on Assets (ROA)	-36.15%
Return on Invested Capital (ROIC)	-45.62%
Return on Capital Employed (ROCE)	-133.95%
Revenue Per Employee	4.01M
Profits Per Employee	-667.29M
Employee Count	52
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	-106.82M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -48.56% in the last 52 weeks. The beta is 0.61, so NeoImmuneTech's price volatility has been lower than the market average.

Beta (5Y)	0.61
52-Week Price Change	-48.56%
50-Day Moving Average	985.20
200-Day Moving Average	1,121.72
Relative Strength Index (RSI)	35.99
Average Volume (20 Days)	1,815,007

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, NeoImmuneTech had revenue of KRW 208.50 million and -34.70 billion in losses. Loss per share was -350.96.

Revenue	208.50M
Gross Profit	6.06B
Operating Income	-35.09B
Pretax Income	-34.81B
Net Income	-34.70B
EBITDA	-31.13B
EBIT	-35.09B
Loss Per Share	-350.96

Balance Sheet

The company has 20.52 billion in cash and 11.12 billion in debt, giving a net cash position of 9.40 billion or 95.10 per share.

Cash & Cash Equivalents	20.52B
Total Debt	11.12B
Net Cash	9.40B
Net Cash Per Share	95.10
Equity (Book Value)	23.74B
Book Value Per Share	240.12
Working Capital	14.45B

Cash Flow

In the last 12 months, operating cash flow was -35.01 billion and capital expenditures -1.60 billion, giving a free cash flow of -36.61 billion.

Operating Cash Flow	-35.01B
Capital Expenditures	-1.60B
Free Cash Flow	-36.61B
FCF Per Share	-370.33

Margins

Gross Margin	n/a
Operating Margin	-16,828.46%
Pretax Margin	-16,693.74%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

NeoImmuneTech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-45.82%
FCF Yield	-48.35%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a